Subcutaneous abatacept in rheumatoid arthritis: current update

Bibliography

• Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27(2):269-81
   PubMed Web of Science ®Google Scholar
• McInnes IB, O’Dell JR. State-of-the-art: rheumatoid arthritis [published erratum appears in Ann Rheum Dis 2011;70:399]. Ann Rheum Dis 2010;69:1898-906
   PubMed Web of Science ®Google Scholar
• Singh JA, Furst DE, Bharat A, et al. Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39
   PubMed Web of Science ®Google Scholar
• Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73(3):516-28
   PubMed Web of Science ®Google Scholar
• Panayi GS, Corrigall V, Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am 2001;27:317-34
   PubMed Web of Science ®Google Scholar
• VanderBorght A, Geusens P, Raus J, et al. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum 2001;31:160-75
   Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16
   PubMed Web of Science ®Google Scholar
• Udagawa N, Kotake S, Kamatani N, et al. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002;4:281-9
   PubMedGoogle Scholar
• Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002;20:29-53
   PubMed Web of Science ®Google Scholar
• Stuart RW, Racke MK. Targeting T cell costimulation in autoimmune disease. Exp Opin Ther Targets 2002;6:275-89
   PubMedGoogle Scholar
• Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13
   PubMed Web of Science ®Google Scholar
• Greene JL, Leytze GM, Emswiler J, et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem 1996;271:26762-71
   PubMed Web of Science ®Google Scholar
• Corbo M, Valencia X, Raymond R, et al. Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity. Ann Rheum Dis 2009;68:S574
   Google Scholar
• Bristol-Myers Squibb. Orencia prescribing information. Available from: http://packageinserts.bms.com/pi/pi_orencia.pdf [Last accessed December 2013]
   Google Scholar
• Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63:2854-64
   Google Scholar
• Genovese M, Pacheco-Tena C, Covarrubias A, et al. Subcutaneous abatacept: long-term data from the ACQUIRE trial. Arthritis Rheum 2012;64(10 Suppl):S201
   Google Scholar
• Kaine J, Gladstein G, Strusberg I, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). Ann Rheum Dis 2012;71:38-44
   PubMed Web of Science ®Google Scholar
• Kaine J, Gladstein G, Strusberg I, et al. Subcutaneous abatacept is effective and well tolerated, with low immunogenicity following temporary withdrawal and re-introduction in the ALLOW LTE. Arthritis Rheum 2011;63:S853
   Google Scholar
• Genovese MC, Schiff M, Luggen ME, et al. Abatacept demonstrates consistent safety and sustained improvements in effi cacy through 4 years of open-label treatment in patients with an inadequate response to anti-TNF therapy. Arthritis Rheum 2009;60(Suppl 10):1689
   Google Scholar
• Genovese MC, Schiff M, Luggen M, et al. Effi cacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-54
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953-63
   PubMed Web of Science ®Google Scholar
• Kremer JM, Russell AS, Emery P, et al. Abatacept demonstrates consistent safety and sustained improvements in effi cacy through 5 years of treatment in biologic-naïve patients with RA. Ann Rheum Dis 2009;68(Suppl 3):FRI0263
   Google Scholar
• Keystone EC, Kremer JM, Russell A, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis 2012;71:857-61
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2012;65:28-38
   Web of Science ®Google Scholar
• Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73(1):86-94
   PubMed Web of Science ®Google Scholar
• Emery P, Burmetster GR, Bykerk VP, et al. Evaluation drug-frr remission with abatacept in early rheumatoid arthritis; study of 24 months from AVERT trial phase IIIb. Ann Rheum Dis 2015;74:19-26
   PubMed Web of Science ®Google Scholar
• Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510-16
   PubMed Web of Science ®Google Scholar
• Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7
   PubMed Web of Science ®Google Scholar
• Alten R, Kaine J, Keystone EC, et al. Safety of subcutaneous abatacept in patients with rheumatoid arthritis (RA): integrated analysis of five clinical trials up to 4.5 years. Ann Rheum Dis 2011;70(Suppl 3):617
   Google Scholar
• Alten R, Kaine J, Keystone EC, et al. Safety profile of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposure. Arthritis Rheum 2011;63:S150
   Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):1-60
   Google Scholar
• Nash P, Nayiager S, Genovese M, et al. Immunogenicity, safety and efficacy of subcutaneous abatacept with or without MTX in patients with rheumatoid arthritis: the Phase III ACCOMPANY study. Arthritis Care Res (Hoboken) 2013;65(5):718-28
   PubMed Web of Science ®Google Scholar
• Simon TA, Smitten AL, Franklin J, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 2009;68:1819-26
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211-15
   PubMed Web of Science ®Google Scholar
• Haggerty HG, Abbott MA, Reilly TP, et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol 2007;34:2365-73
   PubMed Web of Science ®Google Scholar
• Hart MH, de Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;372:196-203
   PubMed Web of Science ®Google Scholar
• Nash P, Ludivico C, Delaet I, et al. Efficacy, safety and pharmacokinetics of subcutaneous abatacept in patients with rheumatoid arthritis, with or without an intravenous (IV) loading dose. Arthritis Rheum 2011;63(Suppl 10):S151
   Google Scholar
• Schiff M, Alten R, Weinblatt M, et al. Weekly subcutaneous abata cept confers comparable onset of treatment response and magnitude of efficacy improvement over 6 months when administered with or without an intravenous abatacept loading dose. Arthritis Rheum 2012;64(Suppl 10):S1076
   Google Scholar